Current efforts to develop an Epstein-Barr virus subunit vaccine are based on the major envelope glycoprotein gp340. Given the central role of CD4+ T cells in regulating immune responses to subunit vaccine antigens, the present study has begun the work of identifying linear epitopes which are recognized by human CD4+ T cells within the 907-amino-acid sequence of gp340. A panel of gp340-specific CD4+ T-cell clones from an Epstein-Barr virus-immune donor were first assayed for their proliferative responses to a series of truncated gp340 molecules expressed from recombinant DNA vectors in rat GH3 cells, by using an autologous B lymphoblastoid cell line as a source of antigen-presenting cells. The first four T-cell clones analyzed all responded to a truncated form of gp340 which contained only the first 260 N-terminal amino acids. These clones were subsequently screened for responses to each of a panel of overlapping synthetic peptides (15-mers) corresponding to the primary amino acid sequence of the first 260 N-terminal amino acids of gp340. One clone (CG2.7) responded specifically to peptides from the region spanning amino acids 61 to 81, while three other clones (CG5.15, CG5.24, and CG5.36) responded specifically to peptides from the region spanning amino acids 163 to 183. Work with individual peptides from these regions allowed finer mapping of the T-cell epitopes and also revealed the highly dose-dependent nature of peptide-induced responses, with inhibitory effects apparent when the most antigenic peptides were present at supraoptimal concentrations. Experiments using homozygous typing B lymphoblastoid cell lines as antigen-presenting cells showed that the T-cell clones with different epitope specificities were restricted through different HLA class II antigens; clone CG2.7 recognized epitope 61-81 in the context of HLA DRw15, whereas clones CG5.15, CG5.24, and CG5.36 recognized epitope 163-183 in the context of HLA DRwll. The present protocol therefore makes a systematic analysis of CD4+ T-cell epitopes within gp340 possible; it will be necessary to screen gp340-specific T-cell clones from a variety of donors to assess the wider influence of HLA class II polymorphism upon epitope choice.
Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis (20) and is strongly linked to at least three human malignancies: large-cell lymphomas of the immunosuppressed, endemic Burkitt's lymphomas, and nasopharyngeal carcinomas (7, 24, 27, 48) . The development of a vaccine capable of preventing either primary EBV infection or EBV-induced disease is an important long-term objective (15) . This necessarily requires the use of a subunit vaccine preparation, and to date most efforts towards this goal have centered on the virus envelope glycoprotein gp340. This glycoprotein is the most abundant component of the viral envelope (11, 40) . It is known to be responsible for virus binding to the EBV receptor molecule CR2 on human B cells (31, 39) , and it is a major target for the virusneutralizing antibody response induced by natural EBV infection in humans (41) .
Testing the efficacy of potential vaccine preparations has required the use of subhuman primate models (14, 28, 29) , in particular the cotton-top tamarin. While there are some differences between the biology of EBV infection in this species, with its limited major histocompatibility complex (MHC) class I polymorphism (45) , and the biology in humans, cotton-top tamarins are clearly susceptible to virusinduced oligoclonal B-cell lymphomas which are similar to those seen in immunosuppressed humans (8, 47) . In recent * Corresponding author.
experiments, preparations of gp340 purified by fast protein liquid chromatography (FPLC) from the membranes of the virus-producing cell line B95.8 have been used to immunize cotton-top tamarins and have protected these animals from subsequent challenge with a lymphomagenic dose of EBV (28, 29) . However, throughout the program of vaccine development in the primate models, it was noted that protection either against viral infection (14) or against virusinduced disease (16) did not always correlate with induced levels of virus-neutralizing antibodies. This highlights the need to investigate cell-mediated immune responses to gp340 both in the experimental animal systems and more importantly, in humans.
Evidence from many systems has indicated a central role for CD4+ rather than CD8+ T cells in the induction of specific immune responses to vaccine antigens, such as subunit preparations which are delivered as exogenously rather than endogenously synthesized proteins (18) . Such vaccine-induced priming of the CD4+ T-cell system has the potential to augment both antibody responses and CD8+ cytotoxic T-cell responses to a subsequent natural infection. It is known that CD4+ T cells recognize foreign antigens not as the native protein but as small peptide fragments which are generated by processing within antigen-presenting cells (APCs) and are presented at the cell surface as a complex with MHC class II molecules (1, 21, 36 (3, 26) . For this reason we first initiated experiments to look for evidence of gp340-spe responses in individuals naturally infected with work showed that purified gp340 could induce short-term proliferation of T cells in culture mononuclear cells from at least some EBV-imm and that gp340-specific CD4+ T-cell clones coul ated from such cultures (43) . Here we report z approach which first uses truncated gp340 mol then uses synthetic peptides to identify specif within the gp340 primary sequence which are rec human CD4+ T-cell clones in the context of part class II antigens.
MATERIALS AND METHODS
T-cell clones. CD4+ T-cell clones were initially from an EBV-immune donor by in vitro stir peripheral blood lymphocytes with FPLC-purifif previously described (43 
RESULTS
Functional analysis of T-cell clones by using truncated gp340 molecules. To first establish the gp340 specificity of T-cell clones, individual CD4+ clones from an EBV-immune donor were tested for their proliferative response to autologous LCL APCs which had been preexposed either to UV-inactivated virions or to FPLC-purified gp340 as the source of antigens. Four clones (CG2.7, CG5.15, CG5.24, and CG5.36) were selected for further study on the basis of their positive responses both to UV-inactivated EBV and to gp340 stimulation. Figure 2A illustrates the results obtained in these initial screening assays with one such clone, CG2.7. We consistently observed some proliferation upon stimulation with autologous LCL APCs alone, but this was much increased upon pretreatment of the APCs with specific antigen. Clones CG5.15, CG5.24, and CG5.36 gave patterns of results similar to that seen for CG2.7.
Subsequently, all four clones were tested for their responses to autologous LCL APCs preexposed to the GH3 cell supernatants, each containing one of the truncated gp340 species illustrated in Fig. 1 . All four clones showed specific proliferation to the whole panel of gp340 species, even that species which contained just the first 260 N-terminal amino acids of the protein; background proliferation in these assays was defined as that induced by APCs preexposed to supernatant from nontransfected GH3 cell cultures. Individual results obtained with one clone, CG2.7, are illustrated in Fig.  2B .
Functional analysis of T-cell clones by using synthetic peptides. Since the above experiments suggested that all four T-cell clones recognized peptide epitopes within the first 260 amino acids of gp340, synthetic 15-mer peptides (with a 12-amino-acid overlap between adjacent peptides) were prepared across this region. In peptide screening assays, each clone was tested for its response to autologous LCL APCs in the presence of individual peptides at a final concentration of 20 p,g/ml. Figure 3 When these responses were analyzed across a range of peptide concentrations, the significance of these initial screening assay results became apparent. Thus, as shown in Fig. 4A , clone CG2.7 did indeed show specific proliferation to peptide 67-81 on autologous LCL APCs but only at an optimal peptide concentration of 20 jig/ml (i.e., the concentration used in the screening assays). However, this same clone was capable of proliferating in response to the neighboring peptides 61-75 and 64-77 at much lower peptide concentrations, with optimal responses at 0.1 to 1 ,ug/ml, whereas responses were suboptimal at the initial screening concentration of 20 ,ug/ml. The stronger antigenicity of peptides 61-75 and 64-77 for clone CG2.7 was further confirmed by using autologous PHA-stimulated T lymphoblasts rather than cells from LCLs as APCs (Fig. 4B) . Here optimal responses to peptides 61-75 and 64-77 were seen at concentrations of 10 to 20 ,ug/ml, whereas it was necessary to go to a concentration of 80 ,ug/ml before there was any detectable response to peptide 67-81. Functional analysis of clone CG5.24 performed by using peptides in the 163-183 region also illustrated the strong peptide dose dependence of the proliferative response. Thus, peptide [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] (identified in the original screening assays) was capable only of inducing specific proliferation when used at a high concentration on autologous LCL APCs. The two neighboring peptides, 166-180 and 169-183, were found to be active at much lower concentrations (0.01 to 0.1 ,ug/ml) on LCL APCs but were inactive at concentrations of 10 Rg/ml or higher (Fig. SA) . Indeed, we frequently observed that the levels of CG5.24 cell proliferation induced by LCL APCs in the presence of high concentrations of these particular peptides fell below the background level induced by LCL APCs alone (Fig. 3) . When tested at 0.1 to 1 ig/ml, peptides 166-180 and 169-183 were also capable of inducing specific proliferation when presented on autologous PHA-stimulated blast APCs, whereas in the same assay peptide 163-177 was inactive even at the highest concentration tested (Fig. SB) Identification of HLA-restricting determinants presenting gp340 peptide epitopes. Since the gp340-specific clones from the donor appeared to fall into two groups with different peptide epitope specificities, we further sought to determine whether these two groups of clones were restricted through different HLA determinants. Earlier work had suggested that all such clones were HLA class II antigen restricted (43) , so in each case MAbs specific to monomorphic regions of the HLA-DR, HLA-DP, or HLA-DQ antigen were tested for their ability to block presentation of the relevant gp340 peptide epitope by autologous cells from LCLs. Stimulation of clone CG2.7 by peptide 61-75 was clearly inhibited in the presence of the anti-HLA-DR MAb L243 but not in the presence of the anti-HLA-DP or anti-HLA-DQ MAbs (Fig.  6A) . Similarly, stimulation of clones CG5.24, CG5.15, and CG5.36 by peptide 169-183 was also inhibited only by the anti-HLA-DR MAb (Fig. 6B and data not shown) .
The inference made from the MAb blocking assays was that all four T-cell clones were restricted through one of the two HLA-DR antigens of the donor (previously identified by conventional serological typing as HLA-DR2 and HLA-DR5). Each of the clones was therefore tested for its ability to respond to a specific antigen (in this case UV-inactivated EBV) when presented on allogenic LCLs matched or mismatched with donor cells at HLA-DR loci. Initial results from this type of analysis indicated that restriction of clone CG2.7 by HLA-DR2 would be likely (data not shown). However, it is known that the DR2 family is itself heterogeneous and contains two major serologically defined subgroups (DRw15 and DRw16), each of which can be subdivided further by primed lymphocyte typing into distinct Dw polymorphisms; DNA sequencing has recently confirmed the existence of these polymorphisms and has identified the A l0 specific amino acid substitutions involved (25) . We therefore sought to determine to what extent clone CG2.7 could respond to specific antigens in the context of each of these different HLA-DR2 molecules. Figure 7A shows representative results from one of three experiments using a relevant panel of homozygous typing LCLs to present UV-inactivated EBV to clone CG2.7; effective stimulation of the clone was restricted to APCs expressing the DRw15, Dw2 subtype of DR2.
In a similar way, initial screening of a range of allogeneic LCLs as APCs for clones CG5.15, CG5.24, and CG5.36 indicated that restriction of these T cells through an antigen of the HLA-DR5 family rather than the HLA-DR2 family was likely (data not shown). More detailed analysis of one of the clones (CG5.24) was carried out using homozygous typing LCLs representing known polymorphisms within HLA-DR5 (25); Fig. 7B illustrates the pattern of results obtained on successive occasions. Three distinct polymorphic antigens within the serologically defined HLA-DRwll subgroup of HLA-DR5 (i.e., Dw5, Dw'FS', and Dw'JVM') were capable of presenting UV-inactivated EBV to clone CG5.24, whereas the serologically distinct HLA-DRw12 antigen was not (Fig. 7B) third, Dw'JVM', induced responses which were much weaker but still consistently above the background levels observed by using HLA-DR-mismatched APCs.
DISCUSSION
Future development of an EBV subunit or synthetic vaccine based on gp340 requires identification of those sites on the molecule that are recognized by virus-neutralizing antibodies and of those sites which elicit T-cell-mediated responses (17, 26) . Mapping of antibody-defined (B cell) epitopes on gp340 is still at a preliminary stage. Many gp340-specific murine MAbs, including several with virusneutralizing ability, are directed to an immunodominant region of gp340 (33) , which further studies have provisionally located within the N-terminal half of the molecule and probably within the first 162 amino acids (39) . However, in no case has MAb specificity been mapped to a defined linear epitope. Indeed, evidence indicates that most anti-gp340 antibodies, whether induced in humans by natural virus infection or in animals by immunization with the native glycoprotein, recognize conformational epitopes on gp340 whose structure and/or accessibility is further influenced by the molecule's host cell-specific pattern of glycosylation (2, 13, 46) .
In contrast, T cells responding to gp340 would be expected to recognize not native antigen but processed linear peptide epitopes presented in the peptide-binding groove of MHC molecules (6, 36, 42) . Here we have concentrated on the identification of CD4+ T-cell epitopes within gp340 because exogenous antigens such as those used in subunit vaccines are processed via the endocytic pathway in APCs and their derived epitopes are selectively presented in the context of MHC class II antigens to the CD4+ T-cell repertoire (30) . This work aimed to develop an efficient protocol for mapping the linear epitopes recognized by gp340-specific CD4+ T-cell clones established in vitro from EBV-immune individuals.
Screening was based first on antigenic fragments of gp340 expressed from recombinant DNA vectors (39, 46) and second on overlapping synthetic peptides corresponding to selected regions of the gp340 amino acid sequence.
This work concentrated on a single EBV-immune donor who was heterozygous at HLA class II loci and from whom a panel of gp340-specific CD4+ T-cell clones had already been established (43) . Interestingly, we found that the first four clones analyzed were all capable of responding not just to UV-inactivated EBV and FPLC-purified gp340 as sources of antigens, but also to an N-terminal fragment of gp340 (amino acids 1 to 260) expressed in rat GH3 cells ( Fig. 1 and  2 ). It is therefore clear that the N-terminal region of gp340 not only elicits strong antibody-mediated recognition but also contains CD4+ T-cell epitopes. The four T-cell clones fell into two groups which recognized different linear epitopes of gp340. Thus, clone CG2.7 recognized three overlapping synthetic peptides spanning the region from amino acids 61 to 81, whereas clones CG5.15, CG5.24, and CG5.36 recognized three different overlapping peptides spanning amino acids 163 to 183 (Fig. 3 through 5) . Since the completion of the present experiments, we have analyzed 10 additional gp340-specific clones from the same donor, and all display either CG2.7-like or CG5.15-, CG5.24-, and CG5.36-like reactivity to synthetic peptides (data not shown). We are therefore confident that the two reactivities described above represent the major components of the CD4+ T-cell response to gp340 in this donor.
It was possible to define antigenic epitopes more precisely by using nested sets of peptides tested over a wide concentration range. Thus, testing a truncated set of peptides within the region spanning amino acids 61 to 81 identified the amino acid sequence spanning positions 65 to 75 (FGQLTPHT KAV) as the minimal epitope for effective stimulation of clone CG2.7 and highlighted the importance of phenylalanine at residue 65 (Table 1) . A reproducible finding made with all four T-cell clones in this type of analysis was the highly dose-dependent nature of peptide-induced T-cell responses ( Fig. 4 and 5 and Table 1 ). When autologous LCL APCs were used, T-cell reactivity to the most antigenic peptides was observed across a fairly broad concentration range; however, there was clear inhibition of responses at supraoptimal peptide doses, akin to the peptide-induced anergy described for CD4+ T-cell clones in other systems (22, 37) .
It is worth noting that the T-cell epitopes described above would not have been highlighted in the primary sequence of gp340 if published algorithms for T-cell epitope identification were used (10, 35) . We therefore favor the present systematic protocol for epitope mapping of gp340, which uses truncated forms of the molecule from the GH3 cell transfectants as an initial procedure and then uses screening with relevant sets of overlapping synthetic peptides on autologous LCL APCs. In view of the dose dependence of the responses, however, it is necessary to screen peptides at two different concentrations (20 and 0.1 ,ug/ml) in order to detect sequences which are stimulatory only at high or only at low J. VIROL.
on November 6, 2017 by guest http://jvi.asm.org/ Downloaded from concentrations. Confirmation of specific peptide-induced responses using autologous PHA-stimulated blast APCs is a useful additional check, although we reproducibly found such cells to be less efficient than LCLs in terms of the peptide concentration required for optimal responses (Fig. 4  and 5 and Table 1 ). While these differences may be due in part to differences in levels of HLA class II antigen expression at the surface of these APCs, cells from LCLs are also a rich source of several lymphokines (19, 44) , which may be acting as accessory factors to promote antigen-specific T-cell responses.
The present results demonstrate the feasibility of mapping T-cell epitopes within the 907-amino-acid primary sequence of gp340 and also begin to show how HLA class II polymorphism can influence epitope choice. Both sets of clones described here were HLA-DR restricted (Fig. 6) , as are all the gp340-specific CD4+ T-cell clones we have analyzed to date (43) (unpublished results). However, clone CG2.7, which recognizes peptide epitope 61-81, was restricted through HLA-DRw15, whereas clones CG5.15, CG5.24, and CG5.36, which recognize peptide epitope 163-183, were restricted through HLA-DRwll (Fig. 7) . Using well-characterized homozygous typing LCLs as APCs, it was possible to ask whether small sequence changes within the presumed peptide-binding site of these HLA class II antigens affected the antigenicity of the HLA class II antigen-peptide complex. Interestingly, the DRwl5(Dw2) antigen could present gp340 to clone CG2.7, whereas the DRw15(Dwl2) antigen, which differs in two p-chain residues predicted to lie on the floor of the peptide-binding site (25) , could not (Fig. 7A) . For the DRwll-restricted clones, however, there was greater tolerance of HLA-DR polymorphisms; thus both the DRwll(Dw5) and DRwll(Dw'FS') antigens could efficiently present gp340, while the DRwll(Dw'JVM') antigen induced less efficient but still significant responses (Fig. 7B) . In this case, DRwll(Dw5) and DRwll(Dw'FS') differ only at a-chain residue 86, predicted to lie at one end of an a-helix which contributes to the peptide-binding site, whereas DRwll(Dw'JVM') has two further substitutions in this a-helix at residues 67 and 71 (25) . Note that these particular experiments were conducted using UV-inactivated EBV rather than peptides as the source of antigens. More recent work using the relevant synthetic peptides suggests that one can compensate for these small differences in the peptidebinding regions of the HLA class II molecules and achieve optimal stimulation of the gp340-specific T-cell clones by increasing the concentration of exogenous peptide added to the system (44a).
The questions of HLA class II polymorphism and epitope choice are clearly important issues in the design of subunit or synthetic vaccines for the outbred human population. To pursue this issue with respect to gp340 will require further studies not only on other HLA-DRw15-or HLA-DRwllpositive donors (to assess the generality of the results obtained with cells from the donor in this experiment) but also on donors expressing other common HLA-DR loci. A number of examples are now appearing in other antigen systems of more promiscuous CD4+ T-cell epitopes which have the capacity to form immunogenic complexes with several polymorphic HLA-DR molecules (4, 32, 38) . These could well be turned to advantage in future vaccine designs, and it is therefore important to determine whether such epitopes exist within gp340.
